NDC product
NUVAXOVID 2026-27
NDC 49281-026 · Sanofi Vaccines US Inc.
Key facts
| Product NDC | 49281-026 |
|---|---|
| Proprietary name | NUVAXOVID 2026-27 |
| Nonproprietary name | NVX-COV2928 |
| Substances | NVX-COV2928 |
| Dosage form | INJECTION, SUSPENSION |
| Route | INTRAMUSCULAR |
| Labeler | Sanofi Vaccines US Inc. |
| Product type | VACCINE |
| Marketing category | BLA |
| Application number | BLA125817 |
| Marketing start | Aug 27, 2026 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: